MCID: VGT001
MIFTS: 54

Vogt-Koyanagi-Harada Disease malady

Categories: Rare diseases, Neuronal diseases, Eye diseases, Immune diseases

Aliases & Classifications for Vogt-Koyanagi-Harada Disease

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Vogt-Koyanagi-Harada Disease:

Name: Vogt-Koyanagi-Harada Disease 11 48 54 50 13
Uveomeningoencephalitic Syndrome 11 39 68
Uveomenigitic Syndrome 48 54
Vogt-Koyanagi-Harada Syndrome 48
 
Vogt-Koyanagi Syndrome 11
Harada's Disease 11
Vkh Syndrome 48
Vkh Disease 48

Characteristics:

Orphanet epidemiological data:

54
vogt-koyanagi-harada disease:
Inheritance: Multigenic/multifactorial; Age of onset: All ages; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:12297
ICD9CM32 363.22, 364.24
MeSH39 D014607
NCIt45 C85218
Orphanet54 ORPHA3437
ICD10 via Orphanet31 H20.8, H30.8

Summaries for Vogt-Koyanagi-Harada Disease

About this section
NIH Rare Diseases:48 Vogt-koyanagi-harada disease (vkh disease) is a condition that involves chronic inflammation of melanocytes, which are specialized cells that produce a pigment called melanin. melanin is the substance that gives skin, hair, and eyes their color. melanin is also found in the retina, where it plays a role in normal vision. people with vkh disease usually develop vision and hearing disturbances first, followed by signs of skin problems. the most common symptoms include headaches, panuveitis, vitiligo, hair loss (alopecia), and inner ear disturbances. neurological symptoms may also occur. the exact cause of vkh disease is not well understood, but research suggests it is an autoimmune disease. it is more common in people with darker skin pigmentation including asian, middle eastern, hispanic, and native american populations. the disease is treated with corticosteroids and other medications. last updated: 9/2/2016

MalaCards based summary: Vogt-Koyanagi-Harada Disease, also known as uveomeningoencephalitic syndrome, is related to hepatitis and alezzandrini syndrome, and has symptoms including Array, Array and Array. An important gene associated with Vogt-Koyanagi-Harada Disease is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways are Melanin biosynthesis and Translocation of ZAP-70 to Immunological synapse. Affiliated tissues include eye, skin and retina, and related mouse phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Increased shRNA abundance (Z-score > 2).

Disease Ontology:11 A hypersensitivity reaction type II disease that is caused by T helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis.

Related Diseases for Vogt-Koyanagi-Harada Disease

About this section

Diseases related to Vogt-Koyanagi-Harada Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 127)
idRelated DiseaseScoreTop Affiliating Genes
1hepatitis30.8HLA-A, HLA-B, HLA-C, HLA-DRB1
2alezzandrini syndrome11.4
3choroiditis10.9
4retinitis10.7
5uveitis10.6
6hepatitis c10.5
7retinal detachment10.5
8headache10.5
9sympathetic ophthalmia10.4
10scleritis10.4
11alopecia10.3
12lymphoma10.3
13posterior scleritis10.3
14melanoma10.3
15neuropathy10.3
16acute posterior multifocal placoid pigment epitheliopathy10.3
17central serous chorioretinopathy10.3
18solid pseudopapillary carcinoma of pancreas10.3HLA-A, HLA-B
19hemoglobin d disease10.3HLA-DQB1, HLA-DRB1
20myopathy, congenital nonprogressive, with moebius sequence and robin sequence10.3HLA-A, HLA-B
21complement component 8 deficiency10.3HLA-DRB1, PTPN22
22mirizzi syndrome10.3HLA-B, HLA-DRB1
23bilateral parasagittal parieto-occipital polymicrogyria10.3HLA-DQB1, HLA-DRB1
24cerebral sarcoidosis10.3HLA-A, HLA-DRB1, IL2RA
25lin-gettig syndrome10.3HLA-DQB1, HLA-DRB1
26sacral nerve root cysts10.3HLA-A, HLA-B, HLA-DRB1
27cataract10.2
28leukemia10.2
29meningoencephalitis10.2
30optic neuritis10.2
31neuritis10.2
32macular holes10.2
33psoriasis10.2
34meningitis10.2
35hernia of ovary and fallopian tube10.2HLA-A, HLA-B, HLA-DRB1
36hashimoto's encephalitis10.2HLA-DRB1, PMEL, TYR
37rete testis adenocarcinoma10.2HLA-A, HLA-DQB1
38nystagmus, congenital motor, autosomal recessive10.2HLA-A, HLA-B, HLA-DRB1
39patau syndrome10.2HLA-A, HLA-DRB1, PTPN22
40acanthoma10.2HLA-A, HLA-B, HLA-DRB1
41immune deficiency, familial variable10.2HLA-B, HLA-DQB1, HLA-DRB1
42periodontosis10.2HLA-A, IL2RA, PTPN22
43cervical adenoid basal carcinoma10.2HLA-B, HLA-DQB1, HLA-DRB1
44myeloid and lymphoid neoplasms associated with pdgfra rearrangement10.2IL2RA, TLR3
45craniosynostosis 610.2PMEL, TYR, TYRP1
46respiratory system disease10.2HLA-B, HLA-DRB1, IL2RA
47neonatal antiphospholipid syndrome10.2HLA-DQB1, HLA-DRB1, IL17A
48demyelinating disease10.2PMEL, TYR
49disease of mental health10.2HLA-B, HLA-DRB1, IL17A
50intracranial hemorrhage in brain cerebrovascular malformations10.2HLA-DRB1, IL2RA, PTPN22

Graphical network of the top 20 diseases related to Vogt-Koyanagi-Harada Disease:



Diseases related to vogt-koyanagi-harada disease

Symptoms & Phenotypes for Vogt-Koyanagi-Harada Disease

About this section

Human phenotypes related to Vogt-Koyanagi-Harada Disease:

 54 64 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the eyelashes64 54 Very frequent (99-80%) HP:0000499
2 glaucoma64 54 Frequent (79-30%) HP:0000501
3 visual impairment64 54 Frequent (79-30%) HP:0000505
4 cataract64 54 Frequent (79-30%) HP:0000518
5 abnormality of the eyebrow64 54 Very frequent (99-80%) HP:0000534
6 retinal detachment64 54 Frequent (79-30%) HP:0000541
7 sensorineural hearing impairment64 54 Very frequent (99-80%) HP:0000407
8 vitiligo64 54 Very frequent (99-80%) HP:0001045
9 hypopigmented skin patches64 54 Very frequent (99-80%) HP:0001053
10 sparse scalp hair64 54 Very frequent (99-80%) HP:0002209
11 premature graying of hair64 54 Very frequent (99-80%) HP:0002216
12 poliosis64 54 Very frequent (99-80%) HP:0002290
13 short stature64 54 Frequent (79-30%) HP:0004322
14 cognitive impairment64 54 Very frequent (99-80%) HP:0100543

GenomeRNAi Phenotypes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-18.6FAS, HLA-DQB1, IL17A, IL2RA, NLRP1, PMEL
2GR00366-A-1926.1HLA-A, HLA-B, HLA-C, IFNA2, HLA-A, HLA-B

MGI Mouse Phenotypes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053798.5CD8A, FAS, HLA-DQB1, IL17A, IL2RA, PTPN22
2MP:00053877.6CD8A, FAS, HLA-DQB1, IL17A, IL2RA, NLRP1
3MP:00053977.5CD8A, FAS, HLA-DQB1, IL17A, IL2RA, NLRP1

Drugs & Therapeutics for Vogt-Koyanagi-Harada Disease

About this section

Drugs for Vogt-Koyanagi-Harada Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bevacizumabapproved, investigationalPhase 32020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
2Angiogenesis InhibitorsPhase 34257
3Angiogenesis Modulating AgentsPhase 34185
4
Azathioprineapproved177446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
5
Cyclosporineapproved, investigational, vet_approved92279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
6
Miconazoleapproved, investigational, vet_approved370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
Mycophenolic acidapproved95224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
8
Mycophenolate mofetilapproved, investigational952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
9
Povidone-iodineapproved16925655-41-8
Synonyms:
 
Betadine
10
Iodine5707553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
11Povidone169
12Immunosuppressive Agents13086
13cadexomer iodine537
14Antibiotics, Antitubercular7180
15Anti-Bacterial Agents11226
16Antifungal Agents3696
17Anti-Infective Agents22062
18Calcineurin Inhibitors1622
19Antirheumatic Agents10956
20Dermatologic Agents5806

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intravitreal Bevacizumab for Inflammatory Neovascular MembranesCompletedNCT00407121Phase 3
2Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 2
3Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective StudyUnknown statusNCT02015351

Search NIH Clinical Center for Vogt-Koyanagi-Harada Disease


Cochrane evidence based reviews: uveomeningoencephalitic syndrome

Genetic Tests for Vogt-Koyanagi-Harada Disease

About this section

Anatomical Context for Vogt-Koyanagi-Harada Disease

About this section

MalaCards organs/tissues related to Vogt-Koyanagi-Harada Disease:

36
Eye, Skin, Retina, T cells, Ovary, Liver, Spinal cord

Publications for Vogt-Koyanagi-Harada Disease

About this section

Articles related to Vogt-Koyanagi-Harada Disease:

(show top 50)    (show all 354)
idTitleAuthorsYear
1
Distinguishing features of acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy on optical coherence tomography angiography and en face optical coherence tomography imaging. (28091938)
2017
2
Detection of Asymptomatic Choroiditis by Fundus Examination in Vogt-Koyanagi-Harada Disease. (27379469)
2016
3
Optical Intensities of Different Compartments of Subretinal Fluid in Acute Vogt-Koyanagi-Harada Disease. (26871896)
2016
4
Comparison of Enhanced Depth Imaging and Swept Source Optical Coherence Tomography in Assessment of Choroidal Thickness in Vogt-Koyanagi-Harada Disease. (27070488)
2016
5
Vogt-Koyanagi-Harada disease: Novel insights into pathophysiology, diagnosis and treatment. (26875727)
2016
6
Choroidal circulation impairment during the anterior recurrence of Vogt-Koyanagi-Harada disease confirmed with indocyanine green angiography and laser speckle flowgraphy. (27079805)
2016
7
Choroidal Vascularity Index in Vogt-Koyanagi-Harada Disease: An EDI-OCT Derived Tool for Monitoring Disease Progression. (27525196)
2016
8
The role of enhanced depth imaging optical coherence tomography in chronic Vogt-Koyanagi-Harada disease. (27048179)
2016
9
FEATURES OF OPTICAL COHERENCE TOMOGRAPHY FOR THE DIAGNOSIS OF VOGT-KOYANAGI-HARADA DISEASE. (27145255)
2016
10
Juvenile Vogt-Koyanagi-Harada Disease in Which Good Visual Prognosis Was Derived from Swift and Definitive Diagnosis. (27110416)
2016
11
Incidence and Management of Glaucoma in Vogt Koyanagi Harada Disease. (26967258)
2016
12
SUB-TENON TRIAMCINOLONE ACETONIDE INJECTION IN A PREGNANT PATIENT WITH VOGT-KOYANAGI-HARADA DISEASE. (28033228)
2016
13
Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. (27535102)
2016
14
Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease. (27775450)
2016
15
Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease. (27582676)
2016
16
Point-of-Care Ultrasound Diagnosis of Bilateral Retinal Detachment Associated With Vogt-Koyanagi-Harada Disease in the Pediatric Emergency Department. (26890299)
2016
17
Vogt-Koyanagi-Harada disease. (27241814)
2016
18
The Role of Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease. (27440118)
2016
19
FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety. (27333235)
2016
20
Response to comment on: Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment. (27084083)
2016
21
Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease. (26900830)
2016
22
Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. (27844182)
2016
23
Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment. (26847039)
2016
24
KIR and HLA Genotypes Implicated in Reduced Killer Lymphocytes Immunity Are Associated with Vogt-Koyanagi-Harada Disease. (27490240)
2016
25
Fundus autofluorescence as a marker of disease severity in Vogt-Koyanagi-Harada disease. (27368955)
2016
26
Changes of choroidal structure after corticosteroid treatment in eyes with Vogt-Koyanagi-Harada disease. (26906951)
2016
27
Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis. (27247899)
2016
28
Investigation of the association between IL10 gene polymorphisms and Vogt-Koyanagi-Harada disease in a Japanese population. (27046676)
2016
29
Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies. (27296490)
2016
30
Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. (27008848)
2016
31
Comment on: Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment. (27084081)
2016
32
Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity. (27003480)
2016
33
A case of unilateral and spontaneously resolving posterior uveitis with overlapping features of Vogt-Koyanagi-Harada disease and Acute Posterior Multifocal Placoid Pigment Epitheliopathy. (27652046)
2016
34
Association of the C2-CFB locus with non-infectious uveitis, specifically predisposed to Vogt-Koyanagi-Harada disease. (26671509)
2016
35
Enhanced Depth SD-OCT Images Reveal Characteristic Choroidal Changes in Patients With Vogt-Koyanagi-Harada Disease. (27842195)
2016
36
Surgical Treatment of Subretinal Fibrosis Caused Macular Detachment in Vogt-Koyanagi-Harada Disease: A Pioneer Study. (27494778)
2016
37
Successful Treatment of Vitiligo Associated with Vogt-Koyanagi-Harada Disease. (27981622)
2016
38
Choroidal thickening prior to anterior recurrence in patients with Vogt-Koyanagi-Harada disease. (26261230)
2015
39
En Face Optical Coherence Tomography Imaging of the Choroid in a Case with Central Serous Chorioretinopathy during the Course of Vogt-Koyanagi-Harada Disease: A Case Report. (26955354)
2015
40
RETINAL PIGMENT EPITHELIUM UNDULATIONS IN ACUTE STAGE OF VOGT-KOYANAGI-HARADA DISEASE: Biomarker for Functional Outcomes After High-Dose Steroid Therapy. (26352553)
2015
41
Correlation between Retinal Changes and Visual Function in Late-Stage Vogt-Koyanagi-Harada Disease: An Optical Coherence Tomography Study. (26301103)
2015
42
Late posterior segment relapses in a series of Vogt-Koyanagi-Harada disease. (25604241)
2015
43
Vogt-Koyanagi-Harada disease in three-year-old boy. (25711345)
2015
44
Vogt-Koyanagi-Harada disease. (26448042)
2015
45
Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography. (25663475)
2015
46
TLR3 and TLR4 But not TLR2 are Involved in Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines Production Through Promoting the Production of Mitochondrial Reactive Oxygen Species. (26238371)
2015
47
Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. (25565265)
2015
48
Posterior subtenon triamcinolone acetonide injection as a primary treatment in eyes with acute Vogt-Koyanagi-Harada disease. (25792626)
2015
49
DETECTION OF CHOROIDAL FOLDS IN PATIENTS WITH VOGT-KOYANAGI-HARADA DISEASE BY RETROMODE SCANNING LASER OPHTHALMOSCOPY. (26444520)
2015
50
SUBFOVEAL CHOROIDAL THICKNESS IN PAPILLITIS TYPE OF VOGT-KOYANAGI-HARADA DISEASE AND IDIOPATHIC OPTIC NEURITIS. (26509220)
2015

Variations for Vogt-Koyanagi-Harada Disease

About this section

Expression for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section
Search GEO for disease gene expression data for Vogt-Koyanagi-Harada Disease.

Pathways for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Pathways related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
19.9TYR, TYRP1
2
Show member pathways
9.7HLA-DQB1, HLA-DRB1, PTPN22
39.6HLA-DQB1, HLA-DRB1, IL17A
49.4HLA-A, HLA-B, HLA-C
5
Show member pathways
9.4HLA-DQB1, HLA-DRB1, IL17A, IL2RA
6
Show member pathways
9.2IL17A, TGFBR3, TLR3
79.1HLA-A, HLA-B, HLA-C, IL2RA
8
Show member pathways
9.1CD8A, HLA-A, HLA-DRB1
9
Show member pathways
9.1CD8A, HLA-A, IL2RA
109.1CD8A, IL17A, IL2RA
11
Show member pathways
8.9CD8A, HLA-A, HLA-DRB1, IL2RA
128.9CD8A, HLA-DQB1, HLA-DRB1, PTPN22
138.8HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
148.8HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
158.8CD8A, HLA-DQB1, HLA-DRB1, IL2RA
168.8CD8A, IFNA2, IL2RA
178.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IL2RA
18
Show member pathways
8.6CD8A, HLA-A, HLA-B, HLA-C
198.6CD8A, HLA-A, HLA-B, HLA-C
20
Show member pathways
8.6FAS, HLA-A, HLA-B, HLA-C, IFNA2
21
Show member pathways
8.5HLA-A, HLA-B, HLA-C, IFNA2, IL17A
22
Show member pathways
8.2HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IFNA2
238.0CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
24
Show member pathways
7.8CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
257.7CD8A, FAS, IL17A, IL2RA, NLRP1, PTPN22
26
Show member pathways
7.7HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IFNA2
27
Show member pathways
7.2FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
28
Show member pathways
6.6CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1
29
Show member pathways
5.7CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1

GO Terms for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Cellular components related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:004261310.5HLA-DQB1, HLA-DRB1
2melanosome membraneGO:003316210.4TYR, TYRP1
3clathrin-coated endocytic vesicle membraneGO:003066910.4HLA-DQB1, HLA-DRB1, TYRP1
4early endosome membraneGO:003190110.2HLA-A, HLA-B, HLA-C
5melanosomeGO:004247010.1PMEL, TYR, TYRP1
6MHC class I protein complexGO:004261210.0HLA-A, HLA-B, HLA-C
7phagocytic vesicle membraneGO:00306709.9HLA-A, HLA-B, HLA-C
8endosome membraneGO:00100089.8HLA-DQB1, HLA-DRB1, TLR3, TYRP1
9ER to Golgi transport vesicle membraneGO:00125079.7HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
10integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
11recycling endosome membraneGO:00550389.4HLA-A, HLA-B, HLA-C
12Golgi membraneGO:00001399.1HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, TLR3
13external side of plasma membraneGO:00098979.0CD8A, FAS, HLA-DRB1, IL17A, IL2RA, TGFBR3
14integral component of plasma membraneGO:00058878.2CD8A, FAS, HLA-A, HLA-B, PMEL, TGFBR3
15cell surfaceGO:00099867.7CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DRB1
16integral component of membraneGO:00160216.4CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1

Biological processes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 21)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:000692410.8FAS, IL2RA
2antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:000250410.7HLA-DQB1, HLA-DRB1
3inflammatory response to antigenic stimulusGO:000243710.7HLA-DRB1, IL2RA
4humoral immune response mediated by circulating immunoglobulinGO:000245510.7HLA-DQB1, HLA-DRB1
5immunoglobulin production involved in immunoglobulin mediated immune responseGO:000238110.6HLA-DQB1, HLA-DRB1
6protection from natural killer cell mediated cytotoxicityGO:004227010.6HLA-A, HLA-B
7melanosome organizationGO:003243810.4PMEL, TYRP1
8necroptotic signaling pathwayGO:009752710.4FAS, TLR3
9melanin biosynthetic processGO:004243810.2PMEL, TYR, TYRP1
10antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentGO:000247910.2HLA-A, HLA-B, HLA-C
11antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:000248010.2HLA-A, HLA-B, HLA-C
12antigen processing and presentation of peptide antigen via MHC class IGO:000247410.2HLA-A, HLA-B, HLA-C
13interferon-gamma-mediated signaling pathwayGO:00603339.5HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
14type I interferon signaling pathwayGO:00603379.4HLA-A, HLA-B, HLA-C, IFNA2
15apoptotic processGO:00069159.4FAS, IFNA2, IL17A, IL2RA, NLRP1
16regulation of immune responseGO:00507769.2CD8A, HLA-A, HLA-B, HLA-C
17inflammatory responseGO:00069548.8FAS, IFNA2, IL17A, IL2RA, NLRP1, TLR3
18antigen processing and presentationGO:00198828.8CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
19viral processGO:00160328.7HLA-A, HLA-B, HLA-C, HLA-DRB1, NLRP1
20immune system processGO:00023767.6CD8A, HLA-A, HLA-B, HLA-C, HLA-DRB1, IL2RA
21immune responseGO:00069557.6CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1

Molecular functions related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II receptor activityGO:003239510.3HLA-DQB1, HLA-DRB1
2peptide antigen bindingGO:00426058.8HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1

Sources for Vogt-Koyanagi-Harada Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet